Study on Ruxolitinib and Enzalutamide for Treating Metastatic Castration-Resistant Prostate Cancer

Inclusion Criteria

• Men aged 18 or older with prostate cancer that has spread and is resistant to hormone therapy.
• Must have previously confirmed prostate cancer.
• Must understand and sign a consent form.
• Must have undergone surgical or medical castration at least 8 weeks before screening, with low testosterone levels.
• Cancer must have progressed after previous treatment with abiraterone, shown by rising PSA levels.
• Must be considered a poor responder to abiraterone based on specific criteria.
• Current or recent treatment must include androgen deprivation therapy (ADT) and abiraterone.
• Willing to undergo a biopsy of metastatic tumors if possible.
• At least 50% of participants must have measurable disease by specific criteria.
• Must have a performance status score of 0 to 2, indicating good overall health.
• Must agree to use contraception during treatment and for 90 days after the last dose.
• Must meet specific blood count and organ function criteria.
• Must have adequate liver and kidney function as determined by specific tests.

Exclusion Criteria

• History of untreated brain metastasis.
• History of seizures or allergies to study drugs.
• Difficulty swallowing pills or gastrointestinal issues affecting drug absorption.
• Uncontrolled high blood pressure.
• Previous chemotherapy for metastatic castration-resistant prostate cancer.
• Unresolved side effects from previous treatments.
• Active infections like hepatitis B, C, or tuberculosis.
• Recent history of heart attack, stroke, or blood clots.
• Life expectancy less than 6 months or difficulty swallowing medications.
• Currently taking certain medications that interact with study drugs.
• High risk of tuberculosis reactivation.
• Severe liver disease.